Literature DB >> 23571297

Intratympanic treatment for tinnitus: a review.

Thomas Meyer1.   

Abstract

Since the 1940s, various attempts have been made to treat peripheral tinnitus by way of intratympanic injection. This administration procedure requires only low concentrations of medication, thanks to the highly targeted delivery to the site of action and comes with minimal systemic exposure. While different compounds have been tested for their effects on tinnitus by intratympanic injection, there has been no breakthrough so far. Accordingly, the clinical use of intratympanic tinnitus treatments has remained limited to date. A more widespread adoption of this approach will require the development of specific medications for peripheral tinnitus, as well as proof of safety and efficacy, which would be determined from randomized controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571297     DOI: 10.4103/1463-1741.110285

Source DB:  PubMed          Journal:  Noise Health        ISSN: 1463-1741            Impact factor:   0.867


  4 in total

1.  [Intratympanic injection therapy for therapy refractory acute hearing loss: A safe option for secondary treatment].

Authors:  G Mühlmeier; S Maier; M Maier; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

2.  Efficacy and safety of AM-101 in the treatment of acute inner ear tinnitus--a double-blind, randomized, placebo-controlled phase II study.

Authors:  Paul van de Heyning; Guido Muehlmeier; Tony Cox; Grazyna Lisowska; Heinz Maier; Krzysztof Morawski; Thomas Meyer
Journal:  Otol Neurotol       Date:  2014-04       Impact factor: 2.311

Review 3.  Sensorineural Tinnitus: Its Pathology and Probable Therapies.

Authors:  Aage R Møller
Journal:  Int J Otolaryngol       Date:  2016-02-08

4.  Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus.

Authors:  Hinrich Staecker; Michael Morelock; Timothy Kramer; Pavel Chrbolka; Joong Ho Ahn; Thomas Meyer
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-13       Impact factor: 3.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.